Vonoprazan fumarate — the first-in-class potassium-competitive acid blocker (P-CAB) representing a fundamentally new mechanism of gastric acid suppression that overcomes the pharmacological limitations of conventional proton pump inhibitors — has become one of the most commercially significant gastroenterology pharmaceutical active pharmaceutical ingredients, with the Vonoprazan...